Get the Stockscreener App
7.35
1.10%
0.08
Decoy Therapeutics Inc stock is traded at $7.35, with a volume of 6,148.
It is up +1.10% in the last 24 hours and down -10.19% over the past month.
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.
See More
Previous Close:
$7.27
Open:
$7.25
24h Volume:
6,148
Relative Volume:
0.04
Market Cap:
$3.91M
Revenue:
-
Net Income/Loss:
$-5.00M
P/E Ratio:
-0.0256
EPS:
-286.8504
Net Cash Flow:
$-4.43M
1W Performance:
-7.55%
1M Performance:
-10.19%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.25
$7.4728
1-Week Range:
$7.24
$8.00
52-Week Range:
$6.3829
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Name
Decoy Therapeutics Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
7.35 | 3.87M | 0 | -5.00M | -4.43M | -286.85 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Ladenburg Thalmann | Buy |
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Stock (DCOY) Latest News
Nabriva Therapeutics (NASDAQ:NBRV) and Decoy Therapeutics (NASDAQ:DCOY) Head to Head Survey - Defense World
If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX) - Stock Titan
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US79400X6022 - marketscreener.com
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FP11 | US79400X6022 - marketscreener.com
Decoy Therapeutics partners with Quantori on AI peptide platform By Investing.com - Investing.com Nigeria
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform - Lelezard
Decoy Therapeutics Inc. Earnings and Revenue – GETTEX:FP11 - TradingView
Debt to equity ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to cash flow ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Free cash flow per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Revenue per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net current asset value per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value to EBITDA ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Non-controlling/minority interest of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to book ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total operating expenses of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
CapEx per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Equity in earnings of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total debt per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Debt to assets ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total common shares outstanding of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBITDA margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Discontinued operations of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics Inc. Statistics – GETTEX:FP11 - TradingView
Gross profit of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Taxes of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Preferred dividends of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Diluted shares outstanding of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
After tax other income/expense of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Diluted net income available to common stockholders of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Pretax income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Non-operating income (total) of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBITDA of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Free float of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics Inc. Revenue Breakdown – GETTEX:FP11 - TradingView
Number of employees of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics (DCOY) Partners with Quantori to Enhance Anti - GuruFocus
Decoy Therapeutics partners with Quantori on AI peptide platform - Investing.com
Decoy Therapeutics enters collaboration with Quantori - TipRanks
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform – NEWSnet Michigan - michigan.newsnetmedia.com
Google Cloud-funded AI aims up to 100-fold faster antiviral peptide design - Stock Titan
Decoy Therapeutics Inc. Revenue Breakdown – MUN:FP11 - TradingView
Decoy Therapeutics Inc. Earnings and Revenue – MUN:FP11 - TradingView
Free cash flow of Decoy Therapeutics Inc. – MUN:FP11 - TradingView
Decoy Therapeutics Inc Stock (DCOY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):